[China BD 2022] Jemincare and Orion enters a license on NaV 1.8 blocker JMKX000623

Announced Date: 2022-05-06 (May 6, 2022)

Asset Name: JMKX000623

Licensor: Shanghai Jemincare Pharmaceutical (China)

Licensee (Buyer): Orion Corporation (Finland)

.

Asset Modality: Small Molecule

Asset Target: NaV 1.8 blocker

Potential Indication: treatment of acute and chronic pain

Current Stage:  IND approval in China

.

Scope of Authority:

Orion will receive exclusive global development and commersialisation rights, excluding the Greater China area (mainland China, Hong Kong, Macau and Taiwan), for a potent and selective NaV 1.8 blocker for the treatment of acute and chronic pain.

Orion will be fully responsible for its own development and commercialisation costs. In addition, Orion will manufacture the products, including active pharmaceutical ingredient, for its markets.

Orion will also receive ownership to certain key patent applications relating to the compound within its own territory.

.

Payment Detail:

Jemincare will receive：

Upfront payment of EUR 15 million,

Development, commercialisation and sales milestone payments, undisclosed.

Tiered royalty of 8% to 15% on future sales in Orion territory.

.

Link:

Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain (orionpharma.com)

.

Note:

Chinese Name of Jemincare 济民可信

Chinese Name of Shanghai Jemincare Pharmaceutical 上海济煜